ALZHEIMER’S DISEASE (AD) STUDY HIGHLIGHTS – Cross-cultural validation of plasma p-tau217 and p-tau181 as precision biomarkers for amyloid PET positivity: An East Asian study in Taiwan and Korea.
This recent study by Lin Y-S et al. evaluated plasma p-tau217 and p-tau181 levels in Korean and Taiwanese populations. The findings indicate that plasma p-tau217 is a highly precise and non-invasive biomarker for predicting amyloid pathology in patients with AD, providing a reliable alternative to amyloid PET imaging for early diagnosis and risk stratification, even in East Asian populations.
Access the full article at: Lin Y-S, Kwon HS, Lee W-J, et al. Cross-cultural validation of plasma p-tau217 and p-tau181 as precision biomarkers for amyloid PET positivity: An East Asian study in Taiwan and Korea. Alzheimer’s Dement. 2025;21:e14565. https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.14565. This article is licensed under a CC-BY license.
How do you see plasma p-tau217 influencing routine clinical practice for early AD diagnosis? Share your insights in the comments below.
